MT2021-11: An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of Epstein-Barr Virus (EBV) disorder - able to walk and do all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours - see link to clinicaltrials.com for additional inclusion criteria

Exclusion Criteria:

- women who are breastfeeding or pregnant - currently active Burkitt, T-cell, natural killer/T-cell lymphoma/LPD, Hodgkin, plasmablastic, transformed lymphoma, active hemophagocytic lymphohistiocytosis, or other malignancies requiring systemic therapy - serious known active infections - additional exclusion criteria apply (study staff will review)

Conditions & Interventions

Conditions:
Cancer, Infectious Diseases
Keywords:
Clinics and Surgery Center (CSC), Epstein-Barr Virus (EBV)

More Information

Description: This research is being done to determine whether the investigational drug tabelecleucel (allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes [EBV-CTLs]) can help people with EBV-associated diseases.
Study Contact: Eric Homan - homa0030@umn.edu
Principal Investigator: Supriya Gupta
Phase: PHASE2
IRB Number: STUDY00013494